Abstract library

33 results for "developing country".
#23 Developing a customized database for NET in a developing country
Introduction: The establishment of a neuroendocrine registry is extremely hard in developing countries. Many patients miss follow-up after surgical procedures and many die in different hospitals with a distinct national security health system number. As in any developing country, Brazil has a large movement of people to urban areas, making the tracking of former addresses impossible for patients who were treated some years prior. Therefore, it is more feasible to evaluate a demographic distribution of neuroendocrine tumors by topography or histological subtype, but the analysis of clinical events, such as progression-free survival, disease-free survival, time to progression or overall survival, is compromised.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: PhD Bernardo Garicochea
#1841 The Characteristics and Survivals of Gastrointestinal Neuroendocrine Tumors, A Single Center Experience from Developing Country
Introduction: Gastrointestinal neuroendocrine tumors (GINETs) are a heterogeneous group of tumors with variable behaviors. We analyzed baseline characteristics and outcomes of GINETs and impact of the tumor grade on the overall survival.
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Doctor Jamshed Ali
Authors: Ali J, Qubtia M, Hassan A U, Ahmad U, ...
#1661 Investigating the Increasing Incidence of Neuroendocrine Tumors in Pakistan as a Result of Increased Awareness
Introduction: Incidence of Neuroendocrine tumors has been increasing worldwide. The reasons for this rising incidence remains unknown.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#1100 Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) represent only 1% of all pancreatic neoplasms by incidence, but 10% by prevalence. Family history of cancer is the only established risk factor so far. The impact of germline genetic variability on PNET risk is poorly understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Federico Canzian
#636 Illness Perceptions, Risk Perception and Worry in Patients with Inherited Paragangliomas
Introduction: Carriers of germline mutations in subunits B and D of the succinate dehydrogenase (SDH) gene are at risk for developing paragangliomas (PGLs). The way a person perceives this risk and worries about it may be influenced by his or her perceptions about PGLs.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD Leonie Van Hulsteijn
#1068 Telotristat Etiprate in a Subset of Carcinoid Syndrome Patients Who Have High Levels of Urinary 5-hydroxyindoleacetic Acid and Frequent Flushing
Introduction: Serotonin is a key mediator of carcinoid syndrome (CS). CS patients (pts) with high levels of urinary 5-hydroxyindoleacetic acid (u5-HIAA, a serotonin metabolite) and >3 flushing episodes/day are at increased risk of developing carcinoid heart disease (CaHD).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Darren Wheeler
#1663 Development of Neuroendocrine Tumors in Patients with a Family History of NET or Any Other Cancer
Introduction: Neuroendocrine tumors are rare. A very little knowledge is known about its risk factors. Studies have shown that NETs may develop as a part of hereditary syndromes.
Conference: 14th Annual ENETS conference (2017)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#1722 New MEN-1 Gene Mutation Implicated in Familiar MEN-1 Syndrome Onset
Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare genetic syndrome associated with an increased risk of developing parathyroid, pituitary and pancreatic neuroendocrine tumors. MEN1 has an autosomal dominant pattern of hereditability and it is usually related to mutations in menin coding gene
Conference: 14th Annual ENETS conference (2017)
Category: Clinical cases/reports
Presenting Author: MD Elisabetta Grego
#1863 Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: A Case-Matched Analysis
Introduction: Neoadjuvant Peptide receptor radionuclide therapy (NPRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNEN) before surgery. Is not clear if NPRRT increases postoperative morbidity
Conference: 14th Annual ENETS conference (2017)
Category: Surgical treatment
Presenting Author: Francesca Muffatti
#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed